AZ-Daiichi, Astellas, Prevnar rival and more—FiercePharmaAsia by Angus Liu Friday, January 3, 2020 Daiichi and AZ's Enhertu as well as and Astellas and Seattle Genetics' Padcev won FDA nods as China approved rivals to Prevnar and Gardasil.
BeiGene's Brukinsa misses in Imbruvica head-to-head by Carly Helfand Monday, December 16, 2019 Brukinsa came up short in a head-to-head tilt with Imbruvica, failing to outdo the blockbuster at producing complete and very good partial responses.
AZ-Daiichi, J&J-Legend, Samsung and more—FiercePharmaAsia by Angus Liu Friday, December 13, 2019 AZ and Daiichi reported "impressive" data for DS-8201. J&J and Legend's CAR-T showed promise in multiple myeloma. South Korea jailed Samsung execs.
BeiGene, eyeing Imbruvica in CLL, touts more early Brukinsa data by Carly Helfand Sunday, December 8, 2019 BeiGene only just won its first Brukinsa nod in MCL. But it’s already pushing to join the CLL field, and Sunday it rolled out more data.
Novartis' CNIBR, BeiGene, Shionogi and more—FiercePharmaAsia by Angus Liu Friday, November 22, 2019 Novartis pivots Shanghai R&D from discovery to development. BeiGene nabs FDA nod for BTK inhibitor Brukinsa. FDA clears Shionogi's antibiotic Fetroja.
AZ's Calquence steps up to challenge Imbruvica with big CLL nod by Carly Helfand, Angus Liu Thursday, November 21, 2019 Imbruvica has enjoyed a nice run in previously untreated CLL over the last few years. But major competition is here in the form of AZ's Calquence.
BeiGene nabs landmark FDA nod for Imbruvica rival Brukinsa by Angus Liu Friday, November 15, 2019 To show Brukinsa is better than AbbVie and J&J's blockbuster Imbruvica, BeiGene is running phase 3 head-to-head trials in blood cancers.
